SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Up 122.2% in March

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 2,000 shares, an increase of 122.2% from the February 28th total of 900 shares. Based on an average daily trading volume, of 29,200 shares, the days-to-cover ratio is currently 0.1 days.

SAB Biotherapeutics Stock Down 7.7 %

Shares of SABSW opened at $0.03 on Friday. SAB Biotherapeutics has a 12-month low of $0.01 and a 12-month high of $0.18. The business has a 50-day simple moving average of $0.04 and a two-hundred day simple moving average of $0.05.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.